 |
|
Further Studies on the Suppression of Corneal Hypersensitivity by Antimetabolites
HOWARD M. LEIBOWITZ, MD;
JAMES H. ELLIOTT, MD
Arch Ophthalmol. 1965;74(6):835-840.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Studies of experimentally induced immune phenomena, as they occur in the cornea, have revealed that this avascular tissue is apparently able to support cellular-mediated as well as antibody-mediated hypersensitivity reactions.1 The authors have previously shown that both types of immune response which follow sensitization of the cornea to a soluble protein antigen (bovine serum albumin [BSA] ) can be inhibited if the antimetabolite 6-mercaptopurine (6-MP) is administered concomitantly with the antigen.2 The drug maintains the cornea in a transparent state and suppresses antibody production as well as the infiltration of the limbus by specific, immunologically competent cells.
In the present study, the initiation of 6-MP therapy was varied with respect to the time of introduction of a foreign protein into the cornea. In this manner, the immunosuppressive efficacy of (1) Pretreatment, (2) short term administration of the drug, and (3) delayed initiation of therapy upon corneal hypersensitivity was investigated.
. . . [Full Text PDF of this Article]
Author Affiliations
Boston
From the Howe Laboratory of Ophthalmology, Harvard University Medical School, Massachusetts Eye and Ear Infirmary.
Footnotes
Submitted May 17, 1965.
Reprint requests to Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, 243 Charles St., Boston, Mass 02114.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
